{
    "nctId": "NCT01220076",
    "briefTitle": "Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+",
    "officialTitle": "Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+",
    "overallStatus": "COMPLETED",
    "conditions": "Non Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SCREENING",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "Evaluate the response to Tamoxifen treatment, in preoperative situations (immediately operable patients) in patients with positive Hormone Receptors (HR+) non-metastatic breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult Females (\u2265 18 years), with effective contraception. The contraceptive should not use estrogen to a derivative. It must be continued during treatment with tamoxifen for at least two months after his arrest.\n* Histologically confirmed diagnosis of invasive breast cancer, previously untreated. Patients have been supported for a breast cancer may be included if a period of at least 2 years between the last systemic treatment of inclusion in the study.\n* Primary tumor hormonopositive: ER and / or PR \u2265 50% by immunohistochemistry.\n* Lack of HER2 overexpression\n* Palpable primary tumor or greater than or equal to 20 mm in diameter, measured by ultrasound\n* Patient scheduled to undergo breast cancer surgery\n* No metastases\n* Clinical Stage M0\n* Performance index \u2264 1 (OMS)\n* Neutrophils WBC \\> or = 1500 / mm3, Platelets \\> or = 100 000/mm3 Hemoglobin \u226510 g/dL\n* Normal liver function: bilirubin \u2264 1.5 x ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5 x ULN (\u2264 5 x ULN if liver metastases).\n* Normal renal function (creatinine \u2264 1.5 mg / dL or creatinine clearance \u2265 60 mL / min)\n* Cardiac function (MUGA scan or ultrasound February\\> 55%) and lung function, 5.2.2 Criteria related to participation in the study:\n* Patient affiliated to social security, Patient has signed and dated consent\n\nNon-Inclusion Criteria:\n\n1. Pregnant or Breastfeeding women\n2. Use of St. John's Wort (herbal tea ...) within 5 days before starting treatment\n3. Consumption of grapefruit juice in the last 5 days of starting treatment\n4. Congenital galactosemia\n5. Glucose and galactose malabsorption\n6. Lactase deficiency\n7. Co-medications that may interfere with cytochrome P450:\n8. Ongoing Enzyme inducers:\n\n   * Antiepileptic drugs: carbamazepine, phenobarbital, phenytoin\n   * Antinfectieux: rifampin, rifabutin, n\u00e9vrirapine, gris\u00e9ofilvine, efavirenz\n9. Ongoing Enzyme Inhibitors:\n\n   * Inhibitors of serotonin reuptake: fluoxetine, paroxetine\n   * Thioridazine. Quinidine\n   * Amiodarone\n   * Ca antagonists: diltiazem, verapamil\n   * azole antifungals ketoconazole, fluconazole, miconazole.\n   * No protease inhibitors: ritonavir, nelfinavir, amprenavir, indinavir.\n   * Macrolides: erythromycin, clarithromycin, josamycin",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}